Biotech Archives - Page 12 of 733

2 minute read

Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients

June 4, 3:18 PM

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.

SNY

3 minute read

Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon

By Upwallstreet

June 4, 1:45 PM

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE:

MRK

2 minute read

Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data

By Vandana Singh

June 4, 12:35 PM

Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results in patchy hair loss.

2 minute read

Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study

By Vandana Singh

June 4, 12:06 PM

Annexon reports positive Phase 3 trial results for ANX005 in Guillain-Barré syndrome, showing significant improvements in disability, muscle strength, and ventilation duration.

ANNX

1 minute read

Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients

By Vandana Singh

June 4, 11:35 AM

Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.

BMY

2 minute read

What’s Going On With Viking Therapeutics Stock On Tuesday?

By Vandana Singh

June 4, 10:29 AM

Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH.

VKTX

1 minute read

Capricor Therapeutics Reports 3-Year Efficacy Results From HOPE-2 Open Label Extension Study Of CAP-1002 In DMD

By Benzinga Newsdesk

June 4, 9:05 AM

--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular Ejection Fraction

CAPR

1 minute read

Cyclacel’s Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

June 4, 8:27 AM

- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.

CYCC

1 minute read

Equillium Announces Topline Data From Phase 2 Study Of EQ101 In Alopecia Areata; 20% Of All Subjects That Completed The 24-week Treatment Period Achieved SALT ≤ 20; EQ101 Was Well Tolerated In Subjects With Alopecia Areata With No Serious Adverse Event…

By Benzinga Newsdesk

June 4, 8:15 AM

20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 2029% of completed subjects with moderate to severe disease (baseline SALT 35 to <95) achieved SALT ≤ 20EQ101 was well tolerated in

1 minute read

Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024

By Benzinga Newsdesk

June 4, 8:10 AM

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and

CUE